Updated on 25 November 2013
"More attention needs to be given to AF-related strokes. With proper management, the risk of AF-related strokes can be potentially reduced. There are medications which prevent the formation of blood clots in the heart and their migration to the brain which causes AF-related stroke. Many patients with AF are not treated with these medications because they do not even know they have AF as it is often asymptomatic and can only be detected through screening," concluded Dr De Silva.
Apixaban is approved to reduce the risk of a first or recurrent stroke or systemic embolism in patients with NVAF. It does not require INR monitoring, has no known dietary restrictions and can be taken with or without food.
"Pfizer and BMS are pleased to collaborate to bring an innovative new treatment to reduce the risk of stroke in patients with atrial fibrillation (AF) to the market" said Ms Christina Teo, country manager, Pfizer Singapore.
"The management and treatment of AF-related stroke has evolved in recent years, and we hope to decrease the incidence of stroke with apixaban," added Mr Binh Thai, general manager, Bristol-Myers Squibb, Singapore.